Jo Ellen Rodgers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jo Ellen Rodgers has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Aldemerdash
Clinical Pharmacy, King Saudi University, Riyadh, Saudi Arabia
3 shared publicationsCarla A. Sueta
UNC School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publicationsKhalid A. Alburikan
Clinical Pharmacy, King Saudi University, Riyadh, Saudi Arabia
3 shared publicationsPatricia P. Chang
Division of Cardiology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, USA
3 shared publicationsRichard H. Tran
Pharmaceutical Product Development, Morrisville, North Carolina
3 shared publicationsSally C. Stearns
Gillings School of Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
3 shared publications
Latest Publications
- 12 September 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (12) , 1225-1234
Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure
Background Use of heart failure-exacerbating medications (HFEMs) may lead to preventable episodes of acute decompensated heart failure (HF). HFEMs use is common in patients with HF, and there may be opportunities to reduce their use from the emergency department (ED). Methods We performed an observational study on patients with HF presenting to EDs within a healthcare system between 1 January 2016 and 31 December 2020. Patients with chronic HF were identified using diagnostic codes within the electronic health record. The cohort was restricted to ambulatory (i.e., discharged to home) ED encounters. Medications, either ordered in the ED or prescribed at ED discharge, were extracted from the medication administration record and identified as potential HFEMs based on the 2016 American Heart Association Scientific Statement. Descriptive statistics were used to summarize the prevalence of HFEM use during ambulatory ED encounters. Exploratory analyses to identify correlates of HFEM use were performed. Results The study cohort included 23,907 ED encounters. ED administration or prescription of HFEMs occurred during 20% of ambulatory ED encounters. HFEM administration in the ED (17%) was more common than HFEM prescription at ED discharge (6%). The most common HFEMs administered in the ED included nonsteroidal anti-inflammatory drugs (11%) and albuterol (7%). Conclusion HFEM use is common in patients with HF seeking ED care, occurring in roughly one-fifth of ambulatory ED encounters. There may be opportunities to optimize medication use among patients with HF in the ED.
- 12 September 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (12) , 1225-1234
Emergency Department Use of Heart Failure-Exacerbating Medications in Patients with Chronic Heart Failure
Background Use of heart failure-exacerbating medications (HFEMs) may lead to preventable episodes of acute decompensated heart failure (HF). HFEMs use is common in patients with HF, and there may be opportunities to reduce their use from the emergency department (ED). Methods We performed an observational study on patients with HF presenting to EDs within a healthcare system between 1 January 2016 and 31 December 2020. Patients with chronic HF were identified using diagnostic codes within the electronic health record. The cohort was restricted to ambulatory (i.e., discharged to home) ED encounters. Medications, either ordered in the ED or prescribed at ED discharge, were extracted from the medication administration record and identified as potential HFEMs based on the 2016 American Heart Association Scientific Statement. Descriptive statistics were used to summarize the prevalence of HFEM use during ambulatory ED encounters. Exploratory analyses to identify correlates of HFEM use were performed. Results The study cohort included 23,907 ED encounters. ED administration or prescription of HFEMs occurred during 20% of ambulatory ED encounters. HFEM administration in the ED (17%) was more common than HFEM prescription at ED discharge (6%). The most common HFEMs administered in the ED included nonsteroidal anti-inflammatory drugs (11%) and albuterol (7%). Conclusion HFEM use is common in patients with HF seeking ED care, occurring in roughly one-fifth of ambulatory ED encounters. There may be opportunities to optimize medication use among patients with HF in the ED.
- 31 July 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (9) , 1509-1527
Obesity and Weight Loss Strategies for Patients With Heart Failure
- 31 July 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (9) , 1509-1527
Obesity and Weight Loss Strategies for Patients With Heart Failure
- 19 June 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (10) , 1661-1676
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
- 19 June 2024
- Published by Elsevier in JACC: Heart Failure
- Vol. 12 (10) , 1661-1676
Obesity, Challenges, and Weight-Loss Strategies for Patients With Ventricular Assist Devices
- Open Access
- 22 January 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (2) , 145-153
Post‐graduate pharmacy fellowships: The current state of affairs
While pharmacy residencies are relatively unanimous in their focus on cultivating quality clinical pharmacists with exceptional clinical knowledge and practice skills, post‐graduate pharmacy fellowships offer training opportunities to develop skills for successful entry into other career types, with major differences between and within various types including pharmaceutical industry, clinical practice, academia/education, and other fellowship programs. In general, pharmaceutical industry fellowships are designed to prepare pharmacy graduates to primarily contribute to various aspects of pharmaceutical drug development and marketing with skills aligned with a specific functional area within pharmaceutical industry. Clinical practice, academia/education, and other research fellowships generally focus on developing research skills in targeted areas ranging from specific therapeutic areas, teaching and learning, or disciplines of research. Most fellowship programs provide training and experiences to develop vital translatable skills such as interpersonal, written, and verbal communication, time and project management, leadership, and teamwork. Conversely, fellowship training can differ considerably, even within individual fellowship types and programs, in specific purpose, structure, required activities, funding, collaborative affiliations, and the specific career a graduate may be qualified to pursue after program completion. The objectives of this article are to differentiate various types of post‐graduate pharmacy fellowship programs and to review strengths and potential areas for improvement across all post‐graduate pharmacy fellowship programs.
- 22 January 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (2) , 145-153
Open AccessPost‐graduate pharmacy fellowships: The current state of affairs
While pharmacy residencies are relatively unanimous in their focus on cultivating quality clinical pharmacists with exceptional clinical knowledge and practice skills, post‐graduate pharmacy fellowships offer training opportunities to develop skills for successful entry into other career types, with major differences between and within various types including pharmaceutical industry, clinical practice, academia/education, and other fellowship programs. In general, pharmaceutical industry fellowships are designed to prepare pharmacy graduates to primarily contribute to various aspects of pharmaceutical drug development and marketing with skills aligned with a specific functional area within pharmaceutical industry. Clinical practice, academia/education, and other research fellowships generally focus on developing research skills in targeted areas ranging from specific therapeutic areas, teaching and learning, or disciplines of research. Most fellowship programs provide training and experiences to develop vital translatable skills such as interpersonal, written, and verbal communication, time and project management, leadership, and teamwork. Conversely, fellowship training can differ considerably, even within individual fellowship types and programs, in specific purpose, structure, required activities, funding, collaborative affiliations, and the specific career a graduate may be qualified to pursue after program completion. The objectives of this article are to differentiate various types of post‐graduate pharmacy fellowship programs and to review strengths and potential areas for improvement across all post‐graduate pharmacy fellowship programs.
- 7 October 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (11) , 837-848
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure
Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been investigated in various settings to establish optimal use, further expanding its indications in patients with heart failure (HF). Although numerous studies have been published, until recently these have primarily involved post hoc analyses from the PARADIGM‐HF study itself with a consistent focus on use of sacubitril/valsartan in patients with HF with reduced ejection fraction (HFrEF). This has led to a gap in the literature regarding utility of sacubitril/valsartan in other HF subpopulations. The aim of this review is to provide a summary of recent clinical trials further expanding use and guideline recommendations for sacubitril/valsartan. The findings of 15 studies, including clinical trials and post hoc analyses, are summarized and describe the use of sacubitril/valsartan in additional HF subpopulations, such as HFrEF following hospitalization for acute decompensated HF and advanced HF, HF with preserved ejection fraction (HFpEF), and HF postmyocardial infarction. In addition, three studies investigating timing of initiation, dose titration regimens, and cost‐effectiveness are examined. Select ongoing trials are also reviewed to demonstrate the continued commitment to further advance care of patients with HF. This comprehensive review serves as a resource for health care providers who pursue optimal utilization of sacubitril/valsartan in their respective clinical practices.
- 7 October 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (11) , 837-848
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure
Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been investigated in various settings to establish optimal use, further expanding its indications in patients with heart failure (HF). Although numerous studies have been published, until recently these have primarily involved post hoc analyses from the PARADIGM‐HF study itself with a consistent focus on use of sacubitril/valsartan in patients with HF with reduced ejection fraction (HFrEF). This has led to a gap in the literature regarding utility of sacubitril/valsartan in other HF subpopulations. The aim of this review is to provide a summary of recent clinical trials further expanding use and guideline recommendations for sacubitril/valsartan. The findings of 15 studies, including clinical trials and post hoc analyses, are summarized and describe the use of sacubitril/valsartan in additional HF subpopulations, such as HFrEF following hospitalization for acute decompensated HF and advanced HF, HF with preserved ejection fraction (HFpEF), and HF postmyocardial infarction. In addition, three studies investigating timing of initiation, dose titration regimens, and cost‐effectiveness are examined. Select ongoing trials are also reviewed to demonstrate the continued commitment to further advance care of patients with HF. This comprehensive review serves as a resource for health care providers who pursue optimal utilization of sacubitril/valsartan in their respective clinical practices.
- 22 November 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (12) , 1066-1080
Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
Objective: To describe the proposed mechanisms of chemotherapy‐associated cardiomyopathy (CAC) and potential cardioprotective therapies for CAC including a comprehensive review of existing systematic analyses, guideline recommendations, and ongoing clinical trials.Data Sources: A literature search of MEDLINE was performed (from 1990 to June 2020) using the following search terms: anthracycline, trastuzumab, cardiomyopathy, cardiotoxicity, primary prevention, angiotensin‐converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta blocker, dexrazoxane (DEX) as well as using individual names from select therapeutic categories.Study Selection and Data Extraction: Existing English language systematic analyses and guidelines were considered.Data Synthesis: The mechanisms of CAC are multifaceted, but various cardioprotective therapies target many of these pathways. To date, anthracyclines and HER‐2 targeted therapies have been the focus of cardioprotective trials to date as they are the most commonly implicated therapies in CAC. While traditional neurohormonal antagonists (ACEIs, ARBs, and beta blockers) and DEX performed favorably in many small clinical trials, the quality of available evidence remains limited. Hence, major guidelines lack consensus on an approach to primary prevention of CAC. Given the uncertain role of preventive therapy, monitoring for a symptomatic or asymptomatic decline in LV function is imperative with prompt evaluation should this occur. Numerous ongoing randomized controlled trials seek to either confirm the findings of these previous studies or identify new therapeutic agents to prevent CAC. Clinical implications are derived from the available literature as well as current guideline recommendations for CAC cardioprotection.Conclusion: At this time, no single therapy has a clear cardioprotective benefit in preventing CAC nor is any therapy strongly recommended by current guidelines. Additional studies are needed to determine the optimal preventative regimens.
- 22 November 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (12) , 1066-1080
Chemotherapy‐associated cardiomyopathy: Mechanisms of toxicity and cardioprotective strategies
Objective: To describe the proposed mechanisms of chemotherapy‐associated cardiomyopathy (CAC) and potential cardioprotective therapies for CAC including a comprehensive review of existing systematic analyses, guideline recommendations, and ongoing clinical trials.Data Sources: A literature search of MEDLINE was performed (from 1990 to June 2020) using the following search terms: anthracycline, trastuzumab, cardiomyopathy, cardiotoxicity, primary prevention, angiotensin‐converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta blocker, dexrazoxane (DEX) as well as using individual names from select therapeutic categories.Study Selection and Data Extraction: Existing English language systematic analyses and guidelines were considered.Data Synthesis: The mechanisms of CAC are multifaceted, but various cardioprotective therapies target many of these pathways. To date, anthracyclines and HER‐2 targeted therapies have been the focus of cardioprotective trials to date as they are the most commonly implicated therapies in CAC. While traditional neurohormonal antagonists (ACEIs, ARBs, and beta blockers) and DEX performed favorably in many small clinical trials, the quality of available evidence remains limited. Hence, major guidelines lack consensus on an approach to primary prevention of CAC. Given the uncertain role of preventive therapy, monitoring for a symptomatic or asymptomatic decline in LV function is imperative with prompt evaluation should this occur. Numerous ongoing randomized controlled trials seek to either confirm the findings of these previous studies or identify new therapeutic agents to prevent CAC. Clinical implications are derived from the available literature as well as current guideline recommendations for CAC cardioprotection.Conclusion: At this time, no single therapy has a clear cardioprotective benefit in preventing CAC nor is any therapy strongly recommended by current guidelines. Additional studies are needed to determine the optimal preventative regimens.
- 1 May 2019
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 25 (5) , 380-400
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee
- 1 May 2019
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 25 (5) , 380-400
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee
- 3 August 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9) , e13367
A case‐control study of the risk factors for developing aspergillosis following cardiac transplant
Background: Invasive aspergillosis (IA) is a significant cause of morbidity and mortality following cardiac transplantation; however, data regarding the predictors of IA in this patient population are limited.Methods: We conducted a case‐control study to identify the risk factors for IA in patients who underwent cardiac transplantation at a single center from 1986 to 2008 (Cohort 1) and 2009 to 2015 (Cohort 2). Cases of IA were matched to two controls from the same year of transplantation, and data were collected from the date of cardiac transplantation to the date of documented Aspergillus infection for each case, or for an equivalent number of days for each control. Univariate and multivariate logistic regressions were used to identify independent predictors of IA in Cohort 1. After 2009, targeted antifungal prophylaxis with oral voriconazole was initiated in patients with risk factors for IA. The incidence of IA was compared pre‐ and postintervention.Results: IA was identified in 23 of 189 (8.0%) patients within Cohort 1. Significant risk factors for IA on multivariate analysis included an increased number of pretransplant hospitalizations (OR 1.81, 95% CI 1.19‐2.76) and posttransplant acute cellular allograft rejection (ACR) (OR 1.99, 95% 1.06‐3.75). Following the implementation of targeted antifungal prophylaxis in 2009, IA was identified in 2 of 107 (2.0%) patients in Cohort 2.Conclusions: Increased pretransplant hospitalizations and posttransplant ACR episodes represent significant risk factors for IA following cardiac transplant. Targeted antifungal prophylaxis in at‐risk patients reduces the incidence of IA.
- 3 August 2018
- Published by Wiley in Clinical Transplantation
- Vol. 32 (9) , e13367
A case‐control study of the risk factors for developing aspergillosis following cardiac transplant
Background: Invasive aspergillosis (IA) is a significant cause of morbidity and mortality following cardiac transplantation; however, data regarding the predictors of IA in this patient population are limited.Methods: We conducted a case‐control study to identify the risk factors for IA in patients who underwent cardiac transplantation at a single center from 1986 to 2008 (Cohort 1) and 2009 to 2015 (Cohort 2). Cases of IA were matched to two controls from the same year of transplantation, and data were collected from the date of cardiac transplantation to the date of documented Aspergillus infection for each case, or for an equivalent number of days for each control. Univariate and multivariate logistic regressions were used to identify independent predictors of IA in Cohort 1. After 2009, targeted antifungal prophylaxis with oral voriconazole was initiated in patients with risk factors for IA. The incidence of IA was compared pre‐ and postintervention.Results: IA was identified in 23 of 189 (8.0%) patients within Cohort 1. Significant risk factors for IA on multivariate analysis included an increased number of pretransplant hospitalizations (OR 1.81, 95% CI 1.19‐2.76) and posttransplant acute cellular allograft rejection (ACR) (OR 1.99, 95% 1.06‐3.75). Following the implementation of targeted antifungal prophylaxis in 2009, IA was identified in 2 of 107 (2.0%) patients in Cohort 2.Conclusions: Increased pretransplant hospitalizations and posttransplant ACR episodes represent significant risk factors for IA following cardiac transplant. Targeted antifungal prophylaxis in at‐risk patients reduces the incidence of IA.
- 22 March 2018
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 38 (4) , 406-416
Guideline‐Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure
Background: Modification of guideline‐directed medical therapy (GDMT) in hospitalized patients with heart failure (HF) has not been extensively evaluated.Methods: The community surveillance arm of the Atherosclerosis Risk in Communities Study identified 6959 HF hospitalizations from 2005–2011. Predictors of GDMT modification and survival were assessed using multivariable logistic regression and Cox proportional hazards models.Results: For 5091 hospitalizations, patient mean age was 75 years, 53% were female, 69% were white, and 81% had acute decompensated heart failure (ADHF). Regarding ejection fraction (EF), 31% of patients had HF with reduced EF (HFrEF), 24% had HF with preserved EF (HFpEF), and 44% were missing EF values. At admission, 52% of patients received angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), 66% β‐blockers (BBs), 9% aldosterone‐receptor antagonists, 16% digoxin, 10% hydralazine, and 29% nitrates. Modification of GDMT occurred in up to 23% of hospitalizations. Significant predictors of GDMT initiation included ADHF and HFrEF; discontinuation of medications was observed with select comorbidities. In HFrEF, initiation of any GDMT was associated with reduced 1‐year all‐cause mortality (adjusted hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.71) as was initiation of ACEI/ARBs, BBs, and digoxin. Discontinuation of any therapy versus maintaining GDMT was associated with greater mortality (HR 1.30, 95% CI 1.02–1.66). Similar trends were observed in HFpEF.Conclusions: Our study suggests that GDMT initiation is associated with increased survival, and discontinuation of therapy is associated with reduced survival in hospitalized patients with HF. Future studies should be conducted to confirm the impact of GDMT therapy modification in this population.
- 22 March 2018
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 38 (4) , 406-416
Guideline‐Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure
Background: Modification of guideline‐directed medical therapy (GDMT) in hospitalized patients with heart failure (HF) has not been extensively evaluated.Methods: The community surveillance arm of the Atherosclerosis Risk in Communities Study identified 6959 HF hospitalizations from 2005–2011. Predictors of GDMT modification and survival were assessed using multivariable logistic regression and Cox proportional hazards models.Results: For 5091 hospitalizations, patient mean age was 75 years, 53% were female, 69% were white, and 81% had acute decompensated heart failure (ADHF). Regarding ejection fraction (EF), 31% of patients had HF with reduced EF (HFrEF), 24% had HF with preserved EF (HFpEF), and 44% were missing EF values. At admission, 52% of patients received angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), 66% β‐blockers (BBs), 9% aldosterone‐receptor antagonists, 16% digoxin, 10% hydralazine, and 29% nitrates. Modification of GDMT occurred in up to 23% of hospitalizations. Significant predictors of GDMT initiation included ADHF and HFrEF; discontinuation of medications was observed with select comorbidities. In HFrEF, initiation of any GDMT was associated with reduced 1‐year all‐cause mortality (adjusted hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.23–0.71) as was initiation of ACEI/ARBs, BBs, and digoxin. Discontinuation of any therapy versus maintaining GDMT was associated with greater mortality (HR 1.30, 95% CI 1.02–1.66). Similar trends were observed in HFpEF.Conclusions: Our study suggests that GDMT initiation is associated with increased survival, and discontinuation of therapy is associated with reduced survival in hospitalized patients with HF. Future studies should be conducted to confirm the impact of GDMT therapy modification in this population.
- 27 February 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (8) , 830
Drug Interactions With Non–Vitamin K Oral Anticoagulants
To the Editor Among 91 330 patients with nonvalvular atrial fibrillation in Taiwan, the use of NOACs with concurrent amiodarone, fluconazole, rifampin, or phenytoin was associated with significantly increased risk of major bleeding.1 We are challenged to identify a biologically plausible explanation for the increased bleeding risk observed with phenytoin and rifampin.
- 27 February 2018
- Published by American Medical Association (AMA) in JAMA
- Vol. 319 (8) , 830
Drug Interactions With Non–Vitamin K Oral Anticoagulants
To the Editor Among 91 330 patients with nonvalvular atrial fibrillation in Taiwan, the use of NOACs with concurrent amiodarone, fluconazole, rifampin, or phenytoin was associated with significantly increased risk of major bleeding.1 We are challenged to identify a biologically plausible explanation for the increased bleeding risk observed with phenytoin and rifampin.